Detect CRE-colonized patients easier and earlier using Thermo Scientific™ Brilliance™ CRE Agar, a chromogenic screening plate that provides results in just 18 hours for carbapenem-resistant Enterobacteriaceae (CRE).
Allow for more timely and targeted treatment of patients while limiting the potential transmission and spread of these pathogenic organisms.
Traditionally, CRE detection has relied on antimicrobial susceptibility testing in conjunction with synergistic methods, like the Modified Hodge Test (MHT). However, MHT is technically demanding, and the results are often subjective and open to interpretation, so is no longer recommended by the CLSI or EUCAST.
As the number of CRE being isolated has increased, especially in geographies such as India, Greece, Israel, Turkey and New York in the U.S.A., so has the need for an accurate, easy-to-use screening method to help identify colonized patients more quickly.
Brilliance CRE Agar makes detecting CRE-colonized patients easy. The formulation contains a modified carbapenem at a level recommended by both EUCAST and CLSI, ensuring reliable results with a wide variety of carbapenem-resistant organisms, including New Delhi Mettalo β-lactamase -1 (NDM-1).
The two-chromogen system differentiates E. coli (pale pink) from the KESC group organisms, which grow blue. Other carbapenem-resistant organisms not from the Enterobacteriaceae family, e.g., Acinetobacter, may grow, but they produce white or naturally pigmented colonies which are easy to spot against the novel turquoise background.
The novel background makes the white or naturally pigmented colonies of non-CRE organisms, like Acinetobacter, easy-to-spot, all of which means you can screen for CRE direct from patient samples in just 18 hours.
Plates are incubated at 37ºC and provide high sensitivity and specificity with results available in just 18 to 24 hours. This allows a rapid response from infection control teams and enables the patient to receive the most appropriate treatment as early as possible.
Accuracy minimizes costs by ensuring that only those in need receive what can be costly treatment.
Detect CRE-colonized patients easier and earlier using Thermo Scientific™ Brilliance™ CRE Agar, a chromogenic screening plate that provides results in just 18 hours for carbapenem-resistant Enterobacteriaceae (CRE).
Allow for more timely and targeted treatment of patients while limiting the potential transmission and spread of these pathogenic organisms.
Traditionally, CRE detection has relied on antimicrobial susceptibility testing in conjunction with synergistic methods, like the Modified Hodge Test (MHT). However, MHT is technically demanding, and the results are often subjective and open to interpretation, so is no longer recommended by the CLSI or EUCAST.
As the number of CRE being isolated has increased, especially in geographies such as India, Greece, Israel, Turkey and New York in the U.S.A., so has the need for an accurate, easy-to-use screening method to help identify colonized patients more quickly.
Brilliance CRE Agar makes detecting CRE-colonized patients easy. The formulation contains a modified carbapenem at a level recommended by both EUCAST and CLSI, ensuring reliable results with a wide variety of carbapenem-resistant organisms, including New Delhi Mettalo β-lactamase -1 (NDM-1).
The two-chromogen system differentiates E. coli (pale pink) from the KESC group organisms, which grow blue. Other carbapenem-resistant organisms not from the Enterobacteriaceae family, e.g., Acinetobacter, may grow, but they produce white or naturally pigmented colonies which are easy to spot against the novel turquoise background.
The novel background makes the white or naturally pigmented colonies of non-CRE organisms, like Acinetobacter, easy-to-spot, all of which means you can screen for CRE direct from patient samples in just 18 hours.
Plates are incubated at 37ºC and provide high sensitivity and specificity with results available in just 18 to 24 hours. This allows a rapid response from infection control teams and enables the patient to receive the most appropriate treatment as early as possible.
Accuracy minimizes costs by ensuring that only those in need receive what can be costly treatment.
